Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
RESEARCH TRIANGLE PARK, N.C., April 26, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its first quarter 2018 financial results will be reported on Tuesday, May 8, 2018.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at https://biocryst.gcs-web.com/events.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at https://biocryst.gcs-web.com/financial-information/sec-filings.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
